Show simple item record

dc.contributor.authorAntolin, AAen_US
dc.contributor.authorWorkman, Pen_US
dc.contributor.authorMestres, Jen_US
dc.contributor.authorAl-Lazikani, Ben_US
dc.date.accessioned2017-11-29T11:52:47Z
dc.date.issued2016-01en_US
dc.identifier.citationCurrent pharmaceutical design, 2016, 22 (46), pp. 6935 - 6945en_US
dc.identifier.issn1381-6128en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/958
dc.identifier.eissn1873-4286en_US
dc.identifier.doi10.2174/1381612822666160923115828en_US
dc.description.abstractOver the past decade, a more comprehensive, large-scale approach to studying cancer genetics and biology has revealed the challenges of tumor heterogeneity, adaption, evolution and drug resistance, while systems-based pharmacology and chemical biology strategies have uncovered a much more complex interaction between drugs and the human proteome than was previously anticipated. In this mini-review we assess the progress and potential of drug polypharmacology in biomarker-driven precision oncology. Polypharmacology not only provides great opportunities for drug repurposing to exploit off-target effects in a new single-target indication but through simultaneous blockade of multiple targets or pathways offers exciting opportunities to slow, overcome or even prevent inherent or adaptive drug resistance. We highlight the many challenges associated with exploiting known or desired polypharmacology in drug design and development, and assess computational and experimental methods to uncover unknown polypharmacology. A comprehensive understanding of the intricate links between polypharmacology, efficacy and safety is urgently needed if we are to tackle the enduring challenge of cancer drug resistance and to fully exploit polypharmacology for the ultimate benefit of cancer patients.en_US
dc.formatPrinten_US
dc.format.extent6935 - 6945en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectHumansen_US
dc.subjectNeoplasmsen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectMedical Oncologyen_US
dc.subjectDrug Resistance, Neoplasmen_US
dc.subjectDrug Repositioningen_US
dc.subjectPolypharmacologyen_US
dc.titlePolypharmacology in Precision Oncology: Current Applications and Future Prospects.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-09-19en_US
rioxxterms.versionofrecord10.2174/1381612822666160923115828en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0en_US
rioxxterms.licenseref.startdate2016-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfCurrent pharmaceutical designen_US
pubs.issue46en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics
pubs.publication-statusPublisheden_US
pubs.volume22en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamComputational Biology and Chemogenomicsen_US
dc.contributor.icrauthorAl-Lazikani, Bissanen_US
dc.contributor.icrauthorWorkman, Paulen_US
dc.contributor.icrauthorAntolin Hernandez, Alberten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/